-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Danburstotug in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Danburstotug in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Danburstotug in Metastatic Melanoma Drug Details: STIA-1015 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Danburstotug in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Danburstotug in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Danburstotug in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crenolanib Besylate in Gastrointestinal Stromal Tumor (GIST)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crenolanib Besylate in Gastrointestinal Stromal Tumor (GIST) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Crenolanib Besylate in Gastrointestinal Stromal Tumor (GIST) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Danburstotug in T-Cell Lymphomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Danburstotug in T-Cell Lymphomas Drug Details: STIA-1015 is under development for the treatment of solid...
-
Product Insights
Natural Killer Cell Lymphomas – Drugs In Development, 2023
Global Markets Direct’s, ‘Natural Killer Cell Lymphomas - Drugs In Development, 2023’, provides an overview of the Natural Killer Cell Lymphomas pipeline landscape. The report provides comprehensive information on the therapeutics under development for Natural Killer Cell Lymphomas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Gallbladder Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Gallbladder Cancer - Drugs In Development, 2023’, provides an overview of the Gallbladder Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gallbladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Esophageal Squamous Cell Carcinoma (ESCC) – Drugs In Development, 2023
Global Markets Direct’s, ‘Esophageal Squamous Cell Carcinoma (ESCC) - Drugs In Development, 2023’, provides an overview of the Esophageal Squamous Cell Carcinoma (ESCC) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Esophageal Squamous Cell Carcinoma (ESCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...